TheraRadar
Data updated: May 26, 2026

DRAX EXAMETAZIME (technetium tc-99m exametazime kit)

Radiopharmaceutical Activity
Immunology Approved 2017-08-17

Drax Exametazime is a radioactive diagnostic tool used to help locate areas of infection or inflammation within the abdomen. It works by labeling a patient's white blood cells, allowing healthcare providers to visualize specific sites of concern, such as intra-abdominal infections or inflammatory bowel disease. This agent is typically used alongside other diagnostic methods to pinpoint the exact location of these conditions.

Source: FDA Label • JUBILANT • Radioactive Diagnostic Agent

How DRAX EXAMETAZIME Works

This agent works by forming a fat-soluble complex that is easily absorbed and held within the patient's white blood cells. Once these labeled cells are reintroduced into the body, they naturally migrate to sites of infection or inflammation, where the radioactive component allows for clear imaging.

1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-08-17
Routes
INTRAVENOUS
Dosage Forms
POWDER

Companies

DRAX EXAMETAZIME Approval History

2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2017 to 2017
Aug 2017 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What DRAX EXAMETAZIME Treats

2 indications

DRAX EXAMETAZIME is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Intra-Abdominal Infection
  • Inflammatory Bowel Disease
Source: FDA Label

DRAX EXAMETAZIME Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

What's emerging in DRAX EXAMETAZIME's indications

See all emerging drugs →

Phase 3 candidates targeting molecules with no FDA-approved drug, in indications DRAX EXAMETAZIME treats. First-in-class if their pivotal trials read out positive.

Drugs Similar to DRAX EXAMETAZIME

3 of 10

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CERETEC
TECHNETIUM TC-99M EXAMETAZIME KIT
2 shared
GE HEALTHCARE
Shared indications:
Intra-Abdominal InfectionInflammatory Bowel Disease
ARIKAYCE KIT
AMIKACIN SULFATE
1 shared
INSMED INC
Shared indications:
CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE
1 shared
CHARTWELL RX
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DRAX EXAMETAZIME FDA Label Details

Indications & Usage

FDA Label (PDF)

DRAX EXAMETAZIME is indicated for the treatment of Intra-Abdominal Infection; Inflammatory Bowel Disease.

Track DRAX EXAMETAZIME with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.